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Liver Unit, Hadassah-Hebrew University Hospital, Jerusalem, IsraelFurther evidence for the potential role of mTOR inhibitors in
the prevention of post-transplantation hepatic ﬁbrosisThe calcineurin inhibitors (CNIs) cyclosporine A and tacroli-
mus have been the cornerstone of anti-rejection drugs in liver
transplantation for the last two decades. Recently, a new genera-
tion of anti-rejection agents is attracting the attention of trans-
plant surgeons and hepatologists. Although not yet approved
for routine use in liver transplantation, the mTOR inhibitors sirol-
imus and everolimus have been shown to be potent anti-rejection
drugs that are less nephrotoxic when compared to CNIs and in
addition seem to increase post-liver transplantation survival of
patients with hepatocellular carcinoma [1,2]. Recent observations
in experimental models of hepatic ﬁbrosis in rats suggest that the
sirolimus mTOR inhibitor Rapamycin also possesses superior
anti-ﬁbrotic properties [3,4]. This property may be of particular
importance in patients undergoing liver transplantation for
hepatitis C virus (HCV) infection. Such patients become uniformly
re-infected with HCV post-transplantation and up to one third
develop an accelerated course of hepatic ﬁbrosis within ﬁve
years. Yet, the cumulative experience using mTOR inhibitors after
liver transplantation is rather limited. The potential anti-ﬁbrotic
activity of sirolimus is of particular interest especially in view
of the recent conclusion supported by a metanalysis which did
not conﬁrm initial expectations of a superior anti-ﬁbrotic effect
of cyclosporine A over tacrolimus in post-transplant HCV patients
[5]. Experimental evidence has already been presented stating
that sirolimus-based immune suppression may prevent angio-
genesis, limit tumor growth and induce microthrombi in liver
tumors. It now becomes important to verify whether the anti-
ﬁbrotic properties of mTOR inhibitors will justify a broader use
of these compounds in post-transplant HCV patients who are
prone to develop an accelerated course of hepatic ﬁbrosis.
In the present issue of the Journal, Patsenker and co-workers
have used an experimental bile duct ligation (BDL) model in rats
to compare the anti-ﬁbrotic activity of four immuno-suppressive
anti-rejection agents: cyclosporine A, tacrolimus, sirolimus, and
everolimus. In their meticulously performed experiments, the
investigators have used a number of complementary methods
to evaluate the anti-ﬁbrotic activity of the tested agents. These
include standard liver function tests, liver histology, immunohis-
tochemistry of inﬂammatory markers and morphometry, hepatic
hydroxy proline analysis, measurement of collagenase activity,Journal of Hepatology 20
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E-mail address: shouval@cc.huji.ac.ilmeasurement of Fibulin-2 mRNA and a number of ﬁbrosis related
gene expression analyses, evaluation of portal pressure as well as
analysis of hepatic free fatty acids and triglycerides. Control
groups included sham operated and non-treated BDL rats. Drug
levels of all four tested compounds injected i.p. were monitored
periodically.
The main ﬁnding of this experimental work suggests that the
mTOR inhibitors sirolimus and everolimus, but not calcineurin
inhibitors, suppress the development of hepatic ﬁbrosis by up
to 70% in bile duct ligated rats and that this effect is associated
with decreased portal pressure. Furthermore, treatment with
mTOR inhibitors led to down-regulation of pro-ﬁbrotic genes,
increased matrix degradation, suppression of inﬂammatory
markers and improved histo-pathologic features manifested by
an increased number of hepatocytes and decreased proliferation
of cholangiocytes and myoﬁbroblast like cells.
The strength of this study is the head to head evaluation of the
four tested compounds using an in vivo model under controlled
experimental conditions. At present, experience with mTOR
inhibitors in liver transplant patients is very limited and informa-
tion on the relative anti-ﬁbrotic potential of sirolimus and ever-
olimus versus calcineurin inhibitors is still unavailable. This is
of particular importance in view of conﬂicting observations
reported in vitro, using cell culture assays of human or rat stellate
cells as well as some contradictory clinical observations in trans-
planted patients treated with calcineurin inhibitors. It may take
some time until such an in depth comparative study as presented
by Pastenker et al. can be conducted in human patients. Thus, the
results of these experiments, using an extensive number of com-
plementary methods in one cohort of animals, contain a wealth of
information which will be of particular interest to investigators
and practitioners in the ﬁeld. The authors of this study emphasize
the potential implication of their results on the management and
prevention of hepatic ﬁbrosis in patients undergoing liver trans-
plantation for chronic HCV infection. Yet, as also stated by the
investigators themselves in their discussion, the study has a lim-
itation due to the selected study model of bile duct ligation. The
generation of hepatic ﬁbrosis in the BDL model is a very rapid
process, which occurs within 2–5 weeks of bile duct ligation as
a result of mechanical obstruction of biliary drainage and cholag-
iole proliferation in a non-infected animal. In contrast, in
humans, HCV infection leads to a necro-inﬂammatory process
which is at least driven in part by an immunological mechanism
leading to a gradual and much slower development of hepatic
ﬁbrosis. Furthermore, additional factors including viral replica-
tion, host and virus genetic properties and use of pharmacologic
agents in the post-transplant setting may also have an impact on11 vol. 55 j 243–244
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generation of hepatic ﬁbrosis. Thus, the mechanism involved in
the fast generation of hepatic ﬁbrosis in the BDL model is
most likely very different from the process which occurs in
human post-transplantation HCV re-infection even if the
post-transplantation ﬁbrosis may evolve in some patients more
rapidly compared to non-transplanted patients. Unfortunately,
all of the available experimental models for HCV infection
such as the transgenic mouse, the uPA/albumin humanized
mouse, the trimera mouse or even the chimpanzee models
have their own limitations especially when it concerns the
development hepatic ﬁbrosis. Therefore, despite its drawback,
the BDL model provides an opportunity to study and compare
the anti-ﬁbrogenic activity of the tested anti-rejection agents
in a controlled and systematic manner. Consequently, the
encouraging results of this study conﬁrming the superior
anti-ﬁbrogenic activity of sirolimus and everolimus justify fur-
ther evaluation in controlled clinical trials in liver transplant
patients infected with HCV.Conﬂict of interest
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